Michigan’s Battle Against Hepatitis C Yields Promising Results Amid National Struggles
In a notable contrast to global successes, the United States faces significant challenges in combating hepatitis C, despite the disease being curable for over a decade. While nations such as Egypt have eradicated chronic hepatitis C as a public health menace, and others like England and Australia are on the brink of achieving this milestone, the U.S. lags behind with approximately 11,000 annual fatalities attributed to the disease, as reported by the World Health Organization.
However, Michigan presents a beacon of hope within the U.S., showcasing a remarkable reduction in chronic hepatitis C cases from about 10,000 in 2018 to a little over 3,000 by 2022. Dr. Natasha Bagdasarian, Michigan’s chief medical executive, expressed pride in this achievement, emphasizing the challenge posed by the disease’s asymptomatic nature, which can leave many unaware of their infection status. “Chronic hepatitis C can be a truly terrible disease,” she stated, highlighting its potential to cause hepatocellular carcinoma, liver cirrhosis, and even necessitate organ transplantation.
The transmission of hepatitis C occurs through direct contact with infected blood, common in situations involving shared drug needles, non-sterile tattoo or piercing practices, healthcare-related needle sticks, and less frequently, from mother to child during pregnancy or through high-risk sexual activities.
Michigan’s progress is largely credited to the “We Treat Hep C” program, which collaborates with community organizations to enhance testing efforts in vulnerable populations. A critical component of the program is the negotiated discounted access to Mavyret, a medication that cures hepatitis C with an eight-week treatment regimen.
While the medication’s market price exceeds $16,000 without insurance, Michigan’s initiatives allow low-income Medicaid recipients to obtain it for just a $1 co-pay, with no copay required for those under the Healthy Michigan Plan. Despite these efforts, Dr. Bagdasarian points out that the fragmented healthcare system in the U.S. remains a significant obstacle. She notes, “The goal is to make hepatitis C detection and treatment available to everyone. But there are people who don’t meet eligibility criteria for Medicaid but can’t afford another form of health insurance. People who lose a job and end up without health insurance. People fall through the cracks.”
Encouragingly, preliminary data from 2025 indicates continued progress in Michigan, with newly identified hepatitis C cases dropping below 2,000. This trend reinforces the importance of targeted programs and accessible healthcare solutions in battling hepatitis C.
—
Read More Michigan News
